NCT04019964View on ClinicalTrials.gov

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 13, 2020

Primary Completion Date

April 23, 2025

Study Completion Date

July 3, 2025

Conditions
Prostate CancerRecurrent Prostate Cancer
Interventions
DRUG

Nivolumab

Nivolumab 480mg intravenously every 4 weeks

Trial Locations (1)

21287

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER